• 1
    Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147S334.
  • 2
    Dykewicz MS, Fineman S, Skoner DP, Nicklas R, Lee R, Blessing-Moore J et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998;81:478518.
  • 3
    Baroody FM. Allergic rhinitis: broader disease effects and implications for management. Otolaryngol Head Neck Surg 2003;128:616631.
  • 4
    Blaiss MS. Cognitive, social, and economic costs of allergic rhinitis. Allergy Asthma Proc 2000;21:713.
  • 5
    Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2000;85:338347.
  • 6
    Young T, Finn L, Kim H. Nasal obstruction as a risk factor for sleep-disordered breathing. The University of Wisconsin Sleep and Respiratory Research Group. J Allergy Clin Immunol 1997;99:S757S762.
  • 7
    Schoenwetter WF, Dupclay L Jr, Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin 2004;20:305317.
  • 8
    Eigenmann PA. Diagnosis of allergy syndromes: do symptoms always mean allergy? Allergy 2005;60(Suppl. 79):69.
  • 9
    Van Cauwenberge P. Advances in allergy management. Allergy 2002;57(Suppl. 75):2936.
  • 10
    Bousquet J, Lund VJ, Van Cauwenberge P, Bremard-Oury C, Mounedji N, Stevens MT et al. Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial. Allergy 2003;58:733741.
  • 11
    Onrust SV, Lamb HM. Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs 1998;56:725745.
  • 12
    Wiseman LR, Benfield P. Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Drugs 1997;53:885907.
  • 13
    Task Force on Allergic Disorders. The Allergy Report, Vol. 1. Milwaukee, WI: American Academy of Allergy, Asthma and Immunology, 2000.; accessed 21 June 2007.
  • 14
    Price D, Bond C, Bouchard J, Costa R, Keenan J, Levy ML et al. International Primary Care Respiratory Group (IPCRG) Guidelines: management of allergic rhinitis. Prim Care Respir J 2006;15:5870.
  • 15
    Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. Br Med J 1998;317:16241629.
  • 16
    Salter M, Biggadike K, Matthews JL, West MR, Haase MV, Farrow SN et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007; doi: DOI: 10.1152/ajplung.00108.2007.
  • 17
    Martin BG, Ratner PH, Hampel FC, Andrews CP, Toler T, Wu W et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007;28:216225.
  • 18
    Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:7783.
  • 19
    Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 1996;98:843845.
  • 20
    Kaiser HB, Naclerio RM, Given J, Toler TN, Ellsworth A, Philpot EE. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007;119:14301437.
  • 21
    Ratner P, Andrews C, Van Bavel J, Toler T, Ellsworth A, Philpot E. Once-daily fluticasone furoate nasal spray (FF) effectively treats ocular symptoms of seasonal allergic rhinitis (SAR) caused by mountain cedar pollen. J Allergy Clin Immunol 2007;119:S231.
  • 22
    Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. First-line treatment of seasonal (ragweed) rhinoconjunctivitis. A randomized management trial comparing a nasal steroid spray and a nonsedating antihistamine. Can Med Assoc J 1997;156:11231131.
  • 23
    Allen A, Down G, Newlands A, Rousell V, Salmon E. Tolerability, safety, pharmacokinetics and bioavailability of the novel intranasal corticosteroid fluticasone furoate in healthy subjects. Ann Allergy Asthma Immunol 2007;98:A89.